A Study of SAL003 in Participants With Hypercholesterolemia and Mixed Dyslipidemia

Inclusion Criteria: * Male or female, aged 18 to 75 years (inclusive). * Fasting LDL-C ≥2.6 mmol/L and \<4.9 mmol/L at screening/randomization. * Meets criteria based on the 2023 Chinese Lipid Management Guidelines (e.g., specific LDL-C levels with certain risk factors, or presence of diabetes). * Fasting triglycerides (TG) ≤5.6 mmol/L at screening/randomization. * Provides written informed consent. Exclusion Criteria: * Diagnosis of familial hypercholesterolemia (HoFH or HeFH). * History of atherosclerotic cardiovascular disease (ASCVD). * Uncontrolled hypertension (SBP ≥160 mmHg or DBP ≥100 mmHg). * Type 1 diabetes or poorly controlled Type 2 diabetes (HbA1c \>8.0%). * Significant hepatic or renal impairment. * Active liver disease or positive for HIV or Syphilis. * History of malignancy within 5 years prior to screening. * Use of any lipid-lowering drugs (statins, ezetimibe, etc.) or traditional Chinese medicines known to affect lipid metabolism within 3 months prior to screening. * Prior treatment with any PCSK9 inhibitor. * Known hypersensitivity to any component of the investigational product or history of severe allergy to antibody therapies. * Any other condition deemed by the investigator to be unsuitable for participation.